ArticlePloS one2026
Benznidazole therapy improves pressure overload and cardiac electrical profile in an experimental model of Angiotensin II infusion-induced hypertension: Mechanistic insights.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Protective Effects of CR6-Interacting Factor 1 Against Angiotensin II-Induced Atrial Fibrillation by Regulating the SIRT1/eNOS Signaling Pathway and Cardiomyocyte Remodeling.Journal of inflammation research · 2026Article
- Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High blood pressure is one of the leading global causes of cardiovascular diseases. The chronic action of high concentrations of angiotensin II (Ang II) promotes arterial hypertension. Ang II acts via AT1 and AT2 receptors. Acting via AT1R, Ang II can induce the production of inflammatory cytokines and reactive oxygen species, promoting oxidative stress, which may influence cardiac electrical traits. In hypertensive patients, a dispersed QTc interval may predict cardiovascular events and mortality. Benznidazole (Bz), an antiprotozoal prodrug, also has immunomodulatory properties. Here, we tested the idea that in a model of Ang II-induced BP overload, cardiomyopathy will be associated with a prolonged QTc interval. Then, we investigated the effects of Bz therapy on BP overload, electrical changes, and oxidant/antioxidant imbalance. C57BL/6 mice were implanted with an osmotic minipump containing Ang II or saline as a control. At 7 days post-surgery (dps), Ang II infusion increased mean BP, which was sustained until 28 dps. Further, the Ang II-infused group had prolonged QTc interval and QRS complex. Bz or the AT1R antagonist losartan (Los) were administered from 7 to 28 dps. Compared with the vehicle-treated group, Los therapy restored mean BP to normal but did not affect long-QTc. At 14 and 28 dps, Bz therapy improved BP, and restored QTc dispersion to normal, while improving RR interval and QRS complex changes. Ang II infusion increased IL-6 concentrations and oxidant/antioxidant imbalance in cardiac tissue. Bz therapy showed a beneficial effect, tending to restore the IL-6 concentrations and oxidant/antioxidant balance to physiological levels, which was correlated with reversal of the dispersed QTc interval. Altogether, our data support that Bz therapy deserves further evaluation as an anti-inflammatory and antioxidant adjuvant tool to improve BP overload and long-QTc syndrome underlying cardiovascular diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.